References
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
- Gamagedara S, Gibbons S, Ma Y. Investigation of urinary pteridine levels as potential biomarkers for noninvasive diagnosis of cancer. Clin. Chim. Acta.412(1–2), 120–128 (2011).
- Slupsky CM, Steed H, Wells TH et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res.16(23), 5835–5841 (2010).
- Hoque MO, Begum S, Topaloglu O et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res.64(15), 5511–5517 (2004).
- Hong CS, Cui J, Ni Z et al. A computational method for prediction of excretory proteins and application to identification of gastric cancer markers in urine. PLoS One6(2), e16875 (2011).
- Szajda SD, Waszkiewicz N, Chojnowska S, Zwierz K. Carbohydrate markers of pancreatic cancer. Biochem. Soc. Trans.39(1), 340–343 (2011).
- Morgan R, Boxall A, Bhatt A et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin. Cancer Res.17(5), 1090–1098 (2011).
- Li H, Li C, Wu H et al. Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma. Proteome Sci.9(1), 21 (2011).
- Lai Y, Ye J, Chen J et al. UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology76(2), 514.e6–514.e11 (2010).
- Morrissey JJ, London AN, Luo J, Kharasch ED. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin. Proc.85(5), 413–421 (2010).
- McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol.32(3), 441–450 (2011).
- Husi H, Stephens N, Cronshaw A et al. Proteomic analysis of urinary upper gastrointestinal cancer markers. Proteomics Clin. Appl.5(5–6), 289–299 (2011).
- Wang XH, Zhang LH, Zhong XY et al. S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am. J. Pathol.177(2), 586–597 (2010).
- Nedjadi T, Kitteringham N, Campbell F et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br. J. Cancer101(7), 1145–1154 (2009).
- Luu HH, Zhou L, Haydon RC et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett.229(1), 135–148 (2005).
- Pine SR, Mechanic LE, Enewold L et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J. Natl. Cancer Inst.103(14), 1112–1122 (2011).
- Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med.2(46), 46ps42 (2010).
- Schröder C, Jacob A, Tonack S et al. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol. Cell Proteomics9(6), 1271–1280 (2010).